Leadership & Pay ·
Cadrenal Therapeutics, Inc. announced the departure of CFO Matthew K. Szot, effective May 28, 2026, and the…
CVKDCadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. announced the departure of CFO Matthew K. Szot, effective May 28, 2026, and the appointment of CEO Quang X. Pham as interim CFO and interim Principal Accounting Officer. Mr. Szot entered into a separation agreement that includes a $365,806.00 severance payment and a fiscal 2026 target cash bonus of $237,903.00.